|Day Low/High||115.19 / 120.84|
|52 Wk Low/High||120.68 / 197.00|
Shares of the maker of Botox are struggling despite its latest results exceeding expectations.
There's been enough news with the lawsuits around this name to get the emotion back into the stock. Emotion often leads to volatility.
In this day and age, companies must be 'disruptors' or get left in the dust.
With shares breaking above the recent, albeit small, pennant, there might be reason for optimism.
David Tepper's Appaloosa LP renews calls for changes at the top.
The approval of esketamine, known as Spravato, for use against severe depression is special -- it is saving lives.
I still believe it will be a big year for buyouts across the biotech industry.
Shares of the Botox competitor could correct/consolidate after a recent surge.
Clearly, the first half of the month shaped up better than the second half.
What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.
Allergan could move higher but some sort of retest of the December low seems in order in the short to intermediate term.
Is it a retest based on the damage the Fed has already done, the result of a breakdown in trade talks or a sign of a slowing global economy?
So far 2019 is proving to be a year where things have a habit of working out right.
The company is set to report earnings on Jan. 29, so traders have a couple of weeks to watch the action.
A three-year decline in the shares of the maker of Botox will take more than a two-week bounce to reverse.
The RMPIA index was up for the year, while the S&P 500, DJIA, Russell 2000 and Nasdaq all finished 2018 in the red.
When I looked at the charts this morning I found a stock that could still decline further.
These are currently situations where companies are facing serious lawsuits.
Let's check the charts and technical indicators for some guidance.
Once the safest stocks in the book, the big-cap drug companies are now toxic.
My target price and panic points have changed, and I am watching for a chance to add or shave some off, depending on which direction the stock takes.
Straying from these names could land you in quicksand as the 4th quarter begins.
Let's check out the charts again so see how far this advance might carry.
There's too much evidence of economic strength, so don't interpret these moves as a sign of a real slowdown.